UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer

Seminars in cancer biology, 2022-02, Vol.79, p.44-57

2022

Volltextzugriff (PDF)

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

PloS one, 2023-03, Vol.18 (3), p.e0282512-e0282512

2023

Volltextzugriff (PDF)

Innovative Technologies Changing Cancer Treatment

Cancers, 2018-06, Vol.10 (6), p.208

2018

Volltextzugriff (PDF)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Translational oncology, 2024-11, Vol.49, p.102073, Article 102073

2024

Volltextzugriff (PDF)

Acquired Resistance to Antibody-Drug Conjugates

Cancers, 2019-03, Vol.11 (3), p.394

2019

Volltextzugriff (PDF)

Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference

Cancers, 2019-08, Vol.11 (8), p.1125

2019

Volltextzugriff (PDF)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2 -Mutated Breast Cancer

Cancers, 2019-05, Vol.11 (6), p.737

2019

Volltextzugriff (PDF)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

British journal of cancer, 2021-03, Vol.124 (7), p.1249-1259

2021

Volltextzugriff (PDF)

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

Clinical cancer research, 2021-02, Vol.27 (3), p.807-818

2021

Volltextzugriff (PDF)

Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells

Cancer chemotherapy and pharmacology, 2024-05, Vol.93 (5), p.427-437

2024

Volltextzugriff (PDF)

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

British journal of cancer, 2023-10, Vol.129 (6), p.1022-1031

2023

Volltextzugriff (PDF)

Research Strategies for Low-Survival Cancers

Cancers, 2021-01, Vol.13 (3), p.528

2021

Volltextzugriff (PDF)

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines

Cellular immunology, 2017-09, Vol.319, p.35-42

2017

Volltextzugriff (PDF)

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

Investigational new drugs, 2019-06, Vol.37 (3), p.441-451

2019

Volltextzugriff (PDF)

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

Investigational new drugs, 2020-10, Vol.38 (5), p.1365-1372

2020

Volltextzugriff (PDF)

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

Investigational new drugs, 2018-08, Vol.36 (4), p.581-589

2018

Volltextzugriff (PDF)

Modulation of P-gp expression by lapatinib

Investigational new drugs, 2011-12, Vol.29 (6), p.1284-1293

2011

Volltextzugriff (PDF)

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

Therapeutic advances in medical oncology, 2019-07, Vol.11, p.1758835919864236

2019

Volltextzugriff (PDF)

Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1773-1773

2020

Volltextzugriff (PDF)

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-28

2022

Volltextzugriff (PDF)

Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-36

2022

Volltextzugriff (PDF)

Abstract B034: Targeting the HER family/Src pathways in ovarian cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (5_Supplement_2), p.B034-B034

2024

Volltextzugriff (PDF)

Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-03-20

2020

Volltextzugriff (PDF)

Preclinical evaluation of Insulin-like growth factor receptor 1

PloS one, 2023-03, Vol.18 (3), p.e0282512

2023

Volltextzugriff (PDF)

Preclinical evaluation of Insulin-like growth factor receptor 1 as a therapeutic targets in triple negative breast cancer

PloS one, 2023-03, Vol.18 (3), p.e0282512

2023

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(148)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

Innovative Technologies Changing Cancer Treatment

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Acquired Resistance to Antibody-Drug Conjugates

Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2 -Mutated Breast Cancer

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

Research Strategies for Low-Survival Cancers

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

Modulation of P-gp expression by lapatinib

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model

Abstract B034: Targeting the HER family/Src pathways in ovarian cancer

Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

Preclinical evaluation of Insulin-like growth factor receptor 1

Preclinical evaluation of Insulin-like growth factor receptor 1 as a therapeutic targets in triple negative breast cancer

Suchergebnisse filtern